Hamed Javan MD
Jewish General Hospital
Dr Javan is a medical doctor, completed Master of Experimental Medicine-Oncology program at McGill University, and working as clinical/research at the Jewish General Hospital with Dr Petr Kavan and Dr Gerald Batist. Dr Javan has established a phase II clinical trial for pancreatic cancer. He has a high interest toward investigator-initiated studies, and running new study protocols. Currently, he is preparing new studies in phase II, III and IV for Pancreatic and Colorectal Cancer. His particular research interest is: Pre—operative FOLFIRINOX in pancreatic cancer.
Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer
Pancreatic Cancer is a disease with poor prognosis. In 2017, its 5-year net survival rate is only 8% with only 2% in metastatic setting and it is third common cause of cancer related death. Only less than 20% of cases are eligible for surgery at diagnosis, so we tried to evaluate the role preoperative FOLFIRINOX in potentially curable pancreatic cancer in retrospective study and clinical trial.
EVEN MORE SEMINARS
Dr Penny Kechagioglou GenesisCare UK
Breast cancer Service of the Future: a service transformation
Dr Qamar Ghafoor University Hospital Birmingham
Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.
Geeta Shetty, MBBS, MS(Gen.Surg), DNB(Gen.Surg), DM, FRCS(Gen.Surg) Sandwell and West Birmingham Hospitals NHS Trust
Chest Wall Perforator Flaps for Partial Breast Reconstruction
Professor Robert Thomas Bedford and Addenbrooke's Cambridge University Hospitals
Evidence based lifestyle strategies after cancer - a research review
Dr Khurum Khan University College London Hospitals
Translational research in GI Oncology- how to make progress?